The North America Postpartum Hemorrhage (PPH) Devices Market would witness market growth of 4.7% CAGR during the forecast period (2022-2028).
Postpartum hemorrhage management presents a variety of difficulties for clinicians. The absence of a clear description and uniform terminology might cause delays in diagnosis and treatment. Treatment varies by etiology, and doctors must be aware of the best assessment tools for determining the reason. When medication is required, it is uncertain which medication should be used first and in what order. It's also necessary to have a better grasp of when to proceed with operations and surgeries, as well as how to choose the best management options. The purpose and clinical issue of PPH management, as noted by the review topic's nominator, is to balance minimally invasive conservative treatment that preserves fertility with the need to control bleeding and achieve hemostasis.
Postpartum hemorrhage leads to excessive bleeding after childbirth and is one of the leading causes of maternal death after child birth across the world. The reason for postpartum hemorrhage has to be determined quickly, and treatment has to begin immediately. Transfer to an operating room with anesthesia support may be necessary to assist with a difficult laceration repair, to correct uterine inversion, to offer analgesia if needed for the evacuation of retained products, or if surgical exploration is necessary. If uterine atony is discovered, medical treatment with uterotonic and pharmacologic treatments is usually the first step. While most institutions administer oxytocin at the time of delivery (see prevention), extra uterotonic medicines may be administered with bimanual massage in the event of hemorrhage. Oxytocin, ergot alkaloids, and prostaglandins are examples of uterotonic agents.
In the United States, postpartum hemorrhage is the greatest cause of maternal death on the day after birth, accounting for around 11% of all maternal deaths. Notably, 54–93% of maternal deaths caused by obstetric bleeding might be avoided. Imprecise health care professional estimation of actual blood loss after birth and the immediate postpartum period is a major cause of delayed response to hemorrhage, according to studies that looked at characteristics linked with identifying and treating postpartum hemorrhage. This mini-crisis is expected to raise the demand for postpartum hemorrhage devices in the region in the next few years. The United States government and individuals spend an exorbitant amount on healthcare, there are many large corporations developing effective solutions and investing significantly in research and development of postpartum hemorrhage devices.
The US market dominated the North America Postpartum Hemorrhage (PPH) Devices Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $279.6 Million by 2028. The Canada market is anticipated to grow at a CAGR of 7.1% during (2022 - 2028). Additionally, The Mexico market would showcase a CAGR of 6.1% during (2022 - 2028).
Based on Product, the market is segmented into Uterine Tamponade Devices, Prefilled Injection System, and Non-Pneumatic Anti-Shock Garment. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
Free Valuable Insights: The Global Postpartum Hemorrhage (PPH) Devices Market is Estimated to reach $1.05 Billion by 2028, at a CAGR of 5.2%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Teleflex, Inc., Becton, Dickinson and Company, Bactiguard Holding AB, Utah Medical Products, Inc., Organon & Co., Cook Medical, Inc., PATH, Obstetrx, Inc., Zoex Corporation, and 3rd Stone Design, Inc.
By Product
By Country
Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
Unique Offerings 